ABCG2 and acute myeloid leukemia: High expression of MRP1 and MRP2, along with breast cancer resistance protein (BCRP or ABCG2), have been proposed as independent predictors of treatment outcome in AML, and the presence of polymorphisms in these genes has been associated with anthracycline response and cardiotoxicity [19,20,21,22,23].